Text Size:AAA

Targeted Therapy for Pancreatic Cancer

Targeted Therapy
What is Targeted Therapy
Targeted Therapy: Targets
Targeted Therapy for Cancer
- Targeted Therapy for Kidney Cancer
- Targeted Therapy for Liver Cancer
- Colorectal Cancer Targeted Therapy
- What is Targeted Therapy for Cancer
- Targeted Therapy for Leukemia
-- Targeted Therapy for Acute Lymphocytic Leukemia
-- Targeted Therapy for Chronic Lymphocytic Leukemia
-- Targeted Therapy for Chronic Myeloid Leukemia
-- Targeted Therapy for Acute Myeloid Leukemia
- Targeted Therapy for Pancreatic Cancer
- Prostate Cancer Targeted Therapy
- Targeted Therapy for Ovarian Cancer
- Melanoma Targeted Therapy
- Targeted Therapy for Lung Cancer
-- Non-Small Cell Lung Cancer (NSCLC) Targeted Therapy
-- Small Cell Lung Cancer Targeted Therapy
-- EGFR Targeted Therapy Lung Cancer
- Targeted Therapy for Breast Cancer
-- Targeted Therapy for Hormone Receptor Positive Breast Cancer
-- Targeted Therapy for HER2 Positive Breast Cancer
-- Targeted Therapy for Triple-Negative Breast Cancer
-- What is Targeted Therapy for Breast Cancer
EGFR Targeted Therapy
HER2 Targeted Therapy
VEGF Targeted Therapy
BRAF Targeted Therapy
ALK Targeted Therapy
Immune Checkpoint Targeted Therapy
Targeted Therapy Drugs
The Differences between Chemotherapy and Targeted Therapy
Side Effects of Targeted Therapy
Oral Targeted Therapy
Targeted Therapy Resistance
How does Targeted Therapy Work
Immunotherapy
Cancer Immunotherapy
Immune checkpoint

Targeted Therapy for Pancreatic Cancer: Introduction

The increased understanding of the molecular and genetic changes associated with tumorigenesis has led to the development of agents that specifically target these alterations. Targets have included KRAS and downstream factors, such as mitogen-activated protein kinase, epidermal growth factor receptor, vascular endothelial growth factor A, and type I receptor for insulin-like growth factor.

Targeted Therapy for Pancreatic Cancer: EGFR

The epidermal growth factor receptor inhibitor EGFR erlotinib has been the only one of these reagents found to significantly prolong survival in phase III trials. In a double-blind, placebo-controlled study, 569 patients with metastatic or locally advanced cancer received either erlotinib with gemcitabine or gemcitabine with placebo. The erlotinib combination produced a modest but statistically significant benefit, prolonging survival by 2 weeks (6.2 vs 5.9 months for patients that received gemcitabine with placebo), which led to its approval by the Food and Drug Administration for treatment of metastatic pancreatic cancer. Integration into clinical practice has been slow, however, because of the cost and the mild but noteworthy side effects of erlotinib (primarily rash and diarrhea).
Additional studies of reagents that target epidermal growth factor receptor have failed to show benefits.

Targeted Therapy for Pancreatic Cancer: VEGF

Reagents that target vascular endothelial growth factor (VEGF) signaling, such as bevacizumab, axitinib, sorafenib, and aflibercept, in combination with gemcitabine, have not been shown to have statistically significant effects on survival compared with gemcitabine alone.

Targeted Therapy for Pancreatic Cancer: KRAS

Activating mutations in KRAS are frequently detected in pancreatic cancer (in 70%–90% of cases) and correlate with the degree of dysplasia in precursor lesions. However, the unique conformation of KRAS and its position in the cell membrane make it a challenge to inhibit. Attempts to manipulate its processing with the farnesyltransferase inhibitor tipifarnib showed no benefits in phase III trials, despite encouraging preclinical data. Efforts to target the Ras pathway have therefore focused on downstream effectors of KRAS activation, such as Raf and mitogen-activated protein kinase. The mitogen-activated protein kinase inhibitor selumetinib has shown results similar to capecitabine (a chemotherapy drug) in phase II studies, and is currently being tested in combination with erlotinib; blocking multiple pathways could have synergistic effects against tumors.

Targeted Therapy for Pancreatic Cancer: Reference

Paulson A S et al. Therapeutic advances in pancreatic cancer[J]. Gastroenterology, 2013, 144(6): 1316-1326.

請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”